Interleukin‐6 polymorphism (–634C/G) in the promotor region and the progression of diabetic nephropathy in Type 2 diabetes

Kitamura, Akane; Hasegawa, Goji; Obayashi, Hiroshi; Kamiuchi, Kenji; Ishii, Michiyo; Yano, Miho; Tanaka, Toru; Yamaguchi, Masatoshi; Shigeta, Hirofumi; Ogata, Masafumi; Nakamura, Naoto; Yoshikawa, Toshikazu

doi:10.1046/j.1464-5491.2002.00844.x

Cited by 110 publications

(111 citation statements)

References 33 publications

(41 reference statements)

Supporting

Mentioning

102

Contrasting

Unclassified

Order By: Relevance

“…It is noteworthy that ethnic variations of SNPs and cytokine expression exist. In the Asian populations, the -634 G allele has been found to increase production/secretion of IL-6 in vitro and is associated with diabetic nephropathy and lung cancer (12,24). One of the objectives of the present study was to investigate the potential influence of the -634 G allele on serum IL-6 level and survival.…”

Section: Discussionmentioning

confidence: 99%

“…The -634G allele has been associated with increased production and secretion of IL-6 by peripheral blood mononuclear cells in vitro (12). It has also been reported as a risk factor for progression of diabetic nephropathy and for lung cancer in conjunction with asthma/atopy (12,24).…”

mentioning

confidence: 99%

“…In Asian populations, however, this SNP is very rare (21 -23) and a more common and important SNP at position -634 (C>G) in the promoter region has been reported (22). The -634G allele has been associated with increased production and secretion of IL-6 by peripheral blood mononuclear cells in vitro (12). It has also been reported as a risk factor for progression of diabetic nephropathy and for lung cancer in conjunction with asthma/atopy (12,24).…”

mentioning

confidence: 99%

See 2 more Smart Citations

Serum Interleukin-6 Level but not Genotype Predicts Survival after Resection in Stages II and III Gastric Carcinoma

Liao¹,

Lin²,

et al. 2008

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: It has been suggested that interleukin-6 (IL-6) is a prognostic indicator for survival in patients with gastric carcinoma, but this has not been proved using survival analysis. In Asians, the -634G allele is associated with increased IL-6 production. The objective of this study was to evaluate the association between serum IL-6 levels, -634G/C polymorphism, and overall survival after resection for gastric carcinoma. Experimental Design: A total of 155 consecutive patients with gastric carcinoma were evaluated. Serum IL-6 levels were analyzed using an enzyme-linked immunoabsorbent assay. Genotype was determined by PCR and restriction fragment length polymorphism. Serum levels and survival were correlated with genotype and clinicopathologic factors. Results: Age and stage, but not -634G/C genotype, were associated with serum IL-6 levels.The median survival for patients with stage II or stage III gastric carcinoma was 1,418 days in patients with low (V13 pg/mL) versus 618 days in patients with high (>13 pg/mL) serum IL-6 levels (P = 0.038). Results of a multivariate analysis showed that serum IL-6 level of >13 pg/mL was a significant predictor of poor survival (hazard ratio, 1.77; 95% confidence interval, 1.07-2.92; P = 0.026).Conclusions: Serum IL-6 level of >13 pg/mL correlates with tumor progression and is an independent predictor of poor survival after resection. In patients with stage II and III gastric carcinoma, serum IL-6 level is more effective than stage as a prognostic indicator. By measuring IL-6, these patients can be divided into two groups with significant differences in survival. The -634G/C polymorphism is not associated with serum IL-6 level or survival.

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Serum Interleukin-6 Level but not Genotype Predicts Survival after Resection in Stages II and III Gastric Carcinoma

Liao¹,

Lin²,

et al. 2008

Clinical Cancer Research

View full text Add to dashboard Cite

show abstract

“…The IL-6 gene is located at p21 of chromosome 7, contains a 1.3 kb coding sequence with five exons and encodes a 23.7 kd protein. It is a polymorphic gene which -634 C/G, -598 A/G, -597 G/A, -572 G/C, -174 G/C polymorphisms were identified in its promoter region (Wang et al 2011;Nakajima et al 1999;Sesso et al 2006;Gao et al 2011;Jenny et al 2002;Baumann and Gauldie 1994;Wypasek et al 2010;Tanaka et al 2005;Sanders et al 2009;Timasheva et al 2008;Kitamura et al 2002;Illig et al 2004). Therefore most of the studies on IL-6 gene focus on promoter region polymorphism analyses.…”

Section: Introductionmentioning

confidence: 99%

Investigation of relationship between IL-6 gene variants and hypertension in Turkish population

et al. 2014

View full text Add to dashboard Cite

show abstract

“…The gene encoding IL-6 is located on chromosome 7p21, and displays a single nucleotide polymorphism (SNP) in the promoter region (−572 C/G (rs1800796), formerly known as -634 C/G) which could affect IL-6 gene transcription and its serum levels (Brull et al, 2001;Kitamura et al, 2002). Recently, a variety of epidemiological studies have been performed to evaluate the association between IL-6 gene −572 C/G polymorphism and T2DM risk in diverse populations.…”

Section: Introductionmentioning

confidence: 99%

Association between the Interleukin‐6 Gene −572 C/G Polymorphism and the Risk of Type 2 Diabetes Mellitus: A Meta‐Analysis of 11,681 Subjects

Yin

Sun²,

Zhang

et al. 2013

Annals of Human Genetics

View full text Add to dashboard Cite

SummaryThe association between the interleukin-6 (IL-6) gene −572 C/G (rs1800796) polymorphism and type 2 diabetes mellitus (T2DM) risk remains controversial. Thus, we performed this meta-analysis by searching PubMed, Embase, Web of Science, CBMdisc and CNKI databases until January 30, 2012. In addition, hand searching of the references of identified articles was performed. A total of 10 case-control studies including 11,681 subjects were selected to evaluate the possible association. Our results showed evidence for significant association between the IL-6 gene −572 C/G polymorphism and T2DM risk (for G allele vs. C allele: odds ratio [OR] = 1.29, 95% confidence interval [CI] = 1.09-1.52, P = 0.002, P = 0.008 after Bonferroni testing; for G/G vs. C/C: OR = 1.89, 95% CI = 1.51-2.37, P < 0.00001, P < 0.00004 after Bonferroni testing; for GG vs. G/C + C/C: OR = 1.75, 95% CI = 1.20-2.56, P = 0.004, P = 0.016 after Bonferroni testing; for G/G + G/C vs. C/C: OR = 1.32, 95% CI = 1.11-1.57, P = 0.001, P = 0.004 after Bonferroni testing). In addition, similar results were obtained in the subgroup analysis based on ethnicity. In summary, the present meta-analysis suggests a significant association between the IL-6 gene −572 G allele and increased risk of T2DM.

show abstract

Interleukin‐6 polymorphism (–634C/G) in the promotor region and the progression of diabetic nephropathy in Type 2 diabetes

Abstract: These results suggest that the IL-6-634C/G polymorphism may be a possible genetic susceptibility factor for the progression of diabetic nephropathy.

Cited by 110 publications

References 33 publications

Serum Interleukin-6 Level but not Genotype Predicts Survival after Resection in Stages II and III Gastric Carcinoma

Serum Interleukin-6 Level but not Genotype Predicts Survival after Resection in Stages II and III Gastric Carcinoma

Investigation of relationship between IL-6 gene variants and hypertension in Turkish population

Association between the Interleukin‐6 Gene −572 C/G Polymorphism and the Risk of Type 2 Diabetes Mellitus: A Meta‐Analysis of 11,681 Subjects

Contact Info

Product

Resources

About